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by the FDA for the treatment of cSSSIs. This study investigated the economic implica-
tions of treating cSSSIs with ceftobiprole, compared to vancomycin or ceftazidime. 
METHODS: A discrete event simulation of acute anti-infective treatment in patients 
with cSSSI was developed. Three copies of patients were created. Each copy was 
assigned one of the treatments (ceftobiprole, vancomycin or ceftazidime). Patients’ 
clinical course was simulated using data from clinical trials of ceftobiprole (patient 
and infection characteristics, cure rates, treatment duration, length of hospital 
stay, adverse event rates, treatment discontinuation, use of subsequent treatments). 
Pathogen coverage status was determined based on the extent to which the treatment 
can cover the pathogens causing the infection (MRSA only, Gram-positive non-MRSA, 
Gram-negative, and other possible combinations). Costs in 2007 USD were taken from 
published sources. Various events (relapse, treatment adjustment, and death) and the 
associated direct medical costs were estimated for a treatment episode (49 days). 
Results are based on 100 simulations of 1,000 patients each. RESULTS: The mean 
cost per patient was estimated to be $19,247 treated with ceftobiprole vs. $19,884 
for vancomycin and $19,721 for ceftazidime. The frequencies of cure, relapse, and 
death were similar across the groups. Less than 1% of patients started on ceftobiprole 
required treatment escalation compared to 23% for vancomycin and ceftazidime, 
indicating that ceftobiprole provided broader coverage against the causing pathogens 
of cSSSIs, thus patients received adequate coverage more promptly. CONCLUSIONS: 
Using ceftobiprole for treatment of cSSSIs is expected to provide similar cure rates 
without increasing costs compared to vancomycin and ceftazidime in the US.
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OBJECTIVES: It is common for published models describing the treatment effective-
ness of managing chronic hepatitis C (CHC) to assume those subjects achieving a 
sustained virologic response (SVR) attain a health utility of one; equivalent to perfect 
health. Our objective was to evaluate the impact of utilising age dependent utility 
weights on the cost effectiveness obtained in a CHC model. METHODS: A Markov 
model describing the natural history of CHC in patients with genotype 1 was devel-
oped to estimate the cost effectiveness of treatment with peginterferon α-2a plus 
ribavarin (PEG) versus interferon α-2b plus ribavarin (IFN). The model was popu-
lated with data and validated using a previously published cost effectiveness model. 
The model was re-calibrated using age dependent utility weights for patients achieving 
SVR and run over a lifetime taking a payer perspective, with both costs and beneﬁts 
discounted at 3.5%. RESULTS: The cost per quality adjusted life years (QALYs) 
of PEG versus IFN obtained using age independent SVR disease state utility value 
of one (base case) were: $1713 for those aged 40 years, $3935 for those aged 50 
years, $8612 for those aged 60 years, and $18,485 for those aged 70 years. The 
same analysis performed using age dependent utility values were: $2,373 for those 
aged 40 years, $5,931 for those aged 50 years, $14,924 for those aged 60 years, 
and $46,123 for those aged 70 years. CONCLUSIONS: Health utility is an important 
driver of cost effectiveness in CHC economic models. Compared to the base case, 
age dependent utility weights substantially increase the cost effectiveness ratios, par-
ticularly in patients aged 60 years or over. The assumption that patients attaining 
SVR have perfect health has the potential to bias decision making and there is, 
therefore, a need for future research that better describes the utility proﬁle associated 
with subjects achieving SVR.
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OBJECTIVES: No differences in viral load (VL) or CD4 + T-cell count at 48 weeks 
were reported for the CASTLE study. However, total cholesterol (TC) levels were 
elevated in 7% and 18% of subjects receiving ATV + RTV and LPV/r, respectively. 
These measures can predict outcomes which affect the future cost of HIV in European 
health systems. Our objective was to examine expected CEA and budget impact of 
LPV/r vs. ATV + RTV for patients similar to the CASTLE population, for Germany, 
Italy, Spain, and UK. METHODS: Using a previously published Markov model of 
HIV disease and newly developed cost data, we compared the cost/QALY and budget 
impact of the two ARV regimens. This model used TC levels at 48 weeks and the 
Framingham equation to include effects of heart disease in the model. Costing used 
2009 health services perspective. RESULTS: The CHD risk favored ATV + RTV, 
resulting in a life expectancy increase of 0.031 QALYs (11 days). Cost effectiveness 
ratios for ATV + RTV were: Germany 3239,700; Italy 3178,856; Spain 3200,531; UK 
£125,139 per QALY. Five year per-patient savings were estimated for LPV/r: Germany 
34057; Italy 32681; Spain 33275; UK £1644. If all subjects were assumed to be 
smokers on anti-hypertensive medication, life expectancy improved by 0.088 QALYs 
(32 days) favoring ATV + RTV. However, the ICERs produced under this scenario 
were 396,812/QALY and £65,279/QALY in Germany and UK, respectively. CON-
CLUSIONS: Based on these cost effectiveness ratios, selecting an ATV + RTV based 
regimen in ARV naïve populations with a CHD risk similar to subjects in the CASTLE 
study does not appear to be a cost effective use of scarce resources in any of the 
countries evaluated. Furthermore, costs associated with the very small added CHD 
risk incurred by LPV/r treatment are more than offset by its short and long term cost 
savings.
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OBJECTIVES: Analyze and identify total time and cost of recruiting patients into a 
randomized clinical trials(RCT) of Motivational Interviewing-based behavioral inter-
ventions to enhance antiretroviral therapy(ART) adherence. Despite numerous feder-
ally funded RCTs, little literature describes the cost of recruiting patients into 
behavioral interventions to enhance ART adherence. METHODS: A secondary data 
analysis of recruitment data collected for Project MOTIV8(R01 MH68197) was 
conducted. Data from 204 HIV+ patients recruited from the Kansas City metro area 
between June of 2004 and August of 2008 were examined for this cost analysis. Direct 
labor costs for all recruitment staff were collected. Microsoft® Excel spreadsheet was 
used to determine number of attempted recruits, average time spent to recruit/enroll 
a patient, number of successful enrollments, and project resources spent on recruit-
ment. Discounting and sensitivity analysis was done to determine the robustness of 
this cost analysis. RESULTS: Over four years Project MOTIV8 screened 1710 patients 
and successfully enrolled 204 participants (11.9%) into the study. The ratio of patients 
approached to successfully enroll was 8.38:1. Ten minutes was the average time spent 
to recruit a patient, however it required 1.4 hours of effort to enroll an eligible patient 
in the study. All costs are reported in 2008 dollar value. The total cost associated with 
four staff members working on the recruitment effort came to $245,626.70(285 hours) 
over the study period. The cost for attempted recruitment was $143.64(10 minute 
average) and the cost for successful enrollment was $1204.05(1.4 hours) for patients 
with HIV. CONCLUSIONS: The costs associated with recruiting participants into a 
study are often overlooked and underestimated. This economic analysis can serve as 
a guide to determine the budget for actively enrolling patients with speciﬁc risk 
behaviors. This data provides information for understanding ancillary costs and will 
help to shed light on unique challenges in the HIV business environment.
INFECTION – Patient-Reported Outcomes Studies
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OBJECTIVES: The primary purpose of this study was to determine the relationship 
between psychotropic medication use and adherence to combination antiretroviral 
therapy. As a secondary analysis, adherence to combination antiretroviral therapy as 
measured by proportion of days covered (PDC) was compared to adherence based on 
the medication possession ratio (MPR) in order to facilitate comparison between the 
results of this study and those of previous studies evaluating antiretroviral adherence. 
METHODS: Data were extracted from Texas Medicaid ﬁles. Included subjects were 
adults with prescription claims for at least three antiretroviral medications indicated 
for treatment of HIV infection within a 3-month period between 1/1/2004 and 
12/31/2004. PDC was deﬁned as the total number of days during the 12-month follow-
up period for which all index antiretroviral medications were available divided by 365 
days, while MPR was deﬁned as the average number of days supplied for all antiret-
roviral medications divided by 365 days (truncated at 100%). Data were analyzed 
using descriptive statistics. RESULTS: When measured by PDC, the mean adherence 
to combination antiretroviral therapy across the entire sample (N = 1,321) was 39.1% 
± 34.6%. Mean adherence was markedly greater when measured by MPR at 70.4% 
± 33.5%, with a mean difference between the two measures of 31.4% ± 36.8%. 
CONCLUSIONS: PDC provides a more conservative estimate of adherence to com-
bination antiretroviral therapy than MPR. MPR results indicate that adherence in this 
study was similar to that found in previous studies using prescription claims data to 
evaluate adherence to combination antiretroviral therapy using modiﬁed versions of 
the MPR (72–81%). Use of PDC to calculate adherence to combination antiretroviral 
therapy may provide more clinically relevant information than other measures since 
concomitant use of all medications in the regimen is theoretically required for syner-
gistic viral suppression and optimal HIV outcomes.
